Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab/hyaluronidase

Next Previous
Drug Profile

Rituximab/hyaluronidase

Alternative Names: MabThera SC; Rituxan Hycela; RITUXAN SC; Rituximab subcutaneous

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Halozyme Therapeutics; Roche
  • Class Antineoplastics; Glycoside hydrolases; Monoclonal antibodies; Polysaccharide lyases
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, First-line therapy) in Argentina (SC, Injection)
  • 28 Feb 2019 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, First-line therapy) in Australia (SC, Injection)
  • 28 Feb 2019 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, First-line therapy) in Brazil (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top